MULTIPLE SCLEROSIS: Treatment of cognitive impairment in secondary progressive MS
Cognitive and neuropsychiatric impairment pose a considerable burden to patients with secondary progressive multiple sclerosis, but no effective therapies have been approved to treat these symptoms. A new trial has shown modest benefits of simvastatin treatment in this context. These results are much welcomed, but require more-rigorous testing.
Refers to Chan, D. et al. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol. 16, 591-600 (2017)